Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind study of LXH-2301 plus febuxostat versus febuxostat alone in gout with hyperuricemia due to underexcretion of uric acid
CTR20243681Phase 2Completed
- Sponsor
- Novabio
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of LXH-2301, febuxostat in gout, hyperuricemia, sponsored by Novabio. Started Oct 2024; status: completed.
02
Drugs
LXH-2301febuxostat
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on CTR20243681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243681.